Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001087294-25-000020
Filing Date
2025-11-07
Accepted
2025-11-07 17:05:30
Documents
59
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cpix-20250930.htm   iXBRL 10-Q 939018
2 EX-31.1 a2025q3-exhibit311.htm EX-31.1 12511
3 EX-31.2 a2025q3-exhibit312.htm EX-31.2 12504
4 EX-32.1 a2025q3-exhibit321.htm EX-32.1 6777
  Complete submission text file 0001087294-25-000020.txt   4734303

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20250930.xsd EX-101.SCH 33210
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20250930_cal.xml EX-101.CAL 54398
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20250930_def.xml EX-101.DEF 130100
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20250930_lab.xml EX-101.LAB 458288
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20250930_pre.xml EX-101.PRE 312160
61 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20250930_htm.xml XML 486827
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 251463498
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)